New River Pharmaceuticals
Quick facts
Phase 3 pipeline
- NRP104 · Neurology / Psychiatry
NRP104 is a prodrug that delivers d-amphetamine to the central nervous system for the treatment of attention-deficit/hyperactivity disorder (ADHD).
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
Frequently asked questions about New River Pharmaceuticals
What is New River Pharmaceuticals's pipeline?
New River Pharmaceuticals has 1 drugs in Phase 3, 0 in Phase 2, 0 in Phase 1. Late-stage candidates include NRP104.
Related
- Sector hub: All tracked pharma companies